Which, of course, they are already doing - and have been for years - with enhanced post approval safety data collection via the PASS system after the approval and commercialisation for use in EPP.
Ann: Media release - First stroke patient with afamelanotide, page-15
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.55 |
Change
-0.030(0.21%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $446.0K | 30.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 167 | $14.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.57 | 21 | 4 |
View Market Depth
| Last trade - 10.27am 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |